Definium Therapeutics (NASDAQ:DFTX) Sets New 52-Week High – Here’s What Happened

Shares of Definium Therapeutics, Inc. (NASDAQ:DFTX) reached a new 52-week high during trading on Thursday . The company traded as high as $18.12 and last traded at $16.96, with a volume of 2164145 shares. The stock had previously closed at $17.15.

Analysts Set New Price Targets

A number of brokerages recently weighed in on DFTX. Canaccord Genuity Group lifted their target price on Definium Therapeutics from $16.00 to $25.00 and gave the company a “buy” rating in a report on Friday, November 7th. Royal Bank Of Canada raised their price objective on Definium Therapeutics from $20.00 to $36.00 and gave the stock an “outperform” rating in a report on Friday. Chardan Capital upgraded Definium Therapeutics to a “strong-buy” rating in a report on Wednesday, November 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Thursday. Finally, Jones Trading assumed coverage on shares of Definium Therapeutics in a research report on Tuesday, December 23rd. They set a “buy” rating and a $61.00 price target on the stock. Three analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $32.11.

Definium Therapeutics Stock Up 2.5%

The firm’s 50 day moving average price is $13.16 and its two-hundred day moving average price is $11.42. The firm has a market capitalization of $1.71 billion, a PE ratio of -8.53 and a beta of 2.57. The company has a quick ratio of 3.30, a current ratio of 3.30 and a debt-to-equity ratio of 0.31.

Definium Therapeutics (NASDAQ:DFTX) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.26). As a group, research analysts forecast that Definium Therapeutics, Inc. will post -1.35 EPS for the current fiscal year.

Insider Buying and Selling

In other Definium Therapeutics news, CEO Robert Barrow sold 25,791 shares of the company’s stock in a transaction that occurred on Friday, December 26th. The stock was sold at an average price of $13.15, for a total value of $339,151.65. Following the transaction, the chief executive officer directly owned 778,477 shares of the company’s stock, valued at $10,236,972.55. This represents a 3.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Mark Sullivan sold 11,276 shares of the stock in a transaction that occurred on Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $148,279.40. Following the transaction, the insider owned 282,576 shares of the company’s stock, valued at approximately $3,715,874.40. This trade represents a 3.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 42,667 shares of company stock worth $561,071. 2.26% of the stock is currently owned by corporate insiders.

Institutional Trading of Definium Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Palumbo Wealth Management LLC grew its holdings in Definium Therapeutics by 18.4% during the 4th quarter. Palumbo Wealth Management LLC now owns 39,002 shares of the company’s stock worth $522,000 after acquiring an additional 6,073 shares in the last quarter. Flagship Harbor Advisors LLC acquired a new stake in shares of Definium Therapeutics in the 4th quarter valued at about $117,000. Bay Rivers Group lifted its position in shares of Definium Therapeutics by 14.3% during the fourth quarter. Bay Rivers Group now owns 16,001 shares of the company’s stock worth $214,000 after purchasing an additional 2,000 shares during the last quarter. FNY Investment Advisers LLC acquired a new position in Definium Therapeutics in the third quarter worth about $107,000. Finally, Caxton Associates LLP acquired a new position in Definium Therapeutics in the third quarter worth about $126,000. 27.91% of the stock is owned by institutional investors and hedge funds.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.